

High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study

Sylvain Manfredi^{1,2}, Olivier Bouché³, Philippe Rougier⁴, Laetitia Dahan⁵, Marie Anne Lorient⁴, Thomas Aparicio⁶, Pierre Luc Etienne⁷, Jean Pierre Lafargue⁸, Cedric Lécaillon⁹, Jean Louis Legoux¹⁰, Karine Le Malicot², Emilie Maillard², Thierry Lecomte¹¹, Faiza Khemissa¹², Gilles Breysacher¹³, Pierre Michel¹⁴, Emmanuel Mitry¹⁵, and Laurent Bedenne^{1,2}

Abstract

High-dose FOLFIRI has an acceptable safety profile and promising efficacy. UDP-glucuronosyltransferase (UGT1A1) polymorphism may be predictive of toxicity and efficacy of irinotecan. This phase II study aimed to evaluate the combination of high-dose FOLFIRI plus bevacizumab in patients with previously untreated metastatic colorectal cancer (MCRC) based on their UGT1A1 genotype. Patients with the UGT1A1 *1/*1 (group 1) or *1/*28 (group 2) genotype received bevacizumab plus high-dose FOLFIRI every 2 weeks. Using the Bryant and Day design with objective response rate and toxicity as the primary endpoints, 54 patients in each group were required with a planned interim analysis after inclusion of 17 patients per group. We planned to stop the trial at the interim analysis if ≤ 7 patients exhibited an objective response (OR) and/or

≥ 3 patients exhibited severe toxicity. At the interim analysis, ORs were higher than the number expected: 52.9% (group 1) and 58.8% (group 2). More than three toxic events occurred in both groups and, according to the interim analysis rule, the trial was closed due to unacceptable toxicity. Recruitment was stopped when 86 patients were included and an analysis on overall population was done for overall survival (OS) and progression-free survival (PFS). The median PFS was 10.7 months (group 1) and 10.4 months (group 2). The median OS was 25.5 months (group 1) and 23.9 months (group 2). This trial does not support the use of the intensive treatment with HD-FOLFIRI plus bevacizumab combination for MCRC in patients with the UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*28 genotype. *Mol Cancer Ther*; 14(12); 2782–8. ©2015 AACR.

¹Hepato-Gastroenterology and Digestive Oncology Department, University Hospital Dijon, INSERM U 866, Digestive Cancer Registry of Burgundy, Dijon, France. ²Fédération Francophone de Cancérologie Digestive, INSERM U866, Dijon, France. ³Department of Gastroenterology, CHU Robert Debré, Reims, France. ⁴Assistance Publique Hôpitaux de Paris, Hôpital Européen G Pompidou and Université Paris Descartes, Paris, France. ⁵Department of Gastroenterology, Assistance Publique - Hôpitaux de Marseille, Hôpital la Timone, et Aix-Marseille Université, Marseille, France. ⁶Department of Gastroenterology and Digestive Oncology, Avicenne Hospital, HUPSSD, APHP and University Paris 13, Bobigny, France. ⁷Department of Medical Oncology, Clinique Armoricaine de Radiologie, St-Brieuc, France. ⁸Department of Gastroenterology, Centre Hospitalier, La Roche sur Yon, France. ⁹Department of Gastroenterology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France. ¹⁰Department of Gastroenterology, Centre Hospitalier Régional, Orléans, France. ¹¹Department of Gastroenterology, CHU de Tours and Université François Rabelais, Chambray les Tours, France. ¹²Department of Gastroenterology, Centre Hospitalier, Perpignan, France. ¹³Department of Gastroenterology, Hôpitaux Civils, Colmar, France. ¹⁴Department of Gastroenterology, Rouen University Hospital and University of Rouen, Rouen, France. ¹⁵Department of Medical Oncology, Institut Curie, Paris - St. Cloud and Université Versailles St. Quentin, UFR des Sciences de la Santé, Saint Cloud, France.

Prior presentation: Presented in part at the 2009 and 2011 ASCO Annual Meetings.

Corresponding Author: Sylvain Manfredi, University Hospital Dijon, INSERM U 866, Digestive Cancer Registry of Burgundy, 21000 Dijon, France. Phone: 33-2-99-28-43-47; Fax: 33-2-99-28-41-89; E-mail: sylvain.manfredi@gmail.com

doi: 10.1158/1535-7163.MCT-15-0293

©2015 American Association for Cancer Research.

Introduction

Irinotecan is a camptothecin analogue with antitumor activity mediated through the inhibition of topoisomerase I. Irinotecan is metabolized by carboxylesterase to form active SN-38, which is further conjugated and detoxified by UDP-glucuronosyltransferase (UGT; ref. 1). Multiple factors determine SN-38 levels, among them UGT ability to inactivate SN-38 by glucuronidation seems to be of importance. Several polymorphisms in UGT, especially the UGT1A1 isoform, have been shown to influence the glucuronidating capacity and, consequently, the pharmacokinetics and toxicity of irinotecan. Different UGT1A1 genotypes have been described. Some of these genotypes are associated with the decreased activity of the corresponding enzyme isoform, leading to constitutional unconjugated jaundice, Crigler-Najjar or Gilbert's syndrome (2), or decreased SN-38 glucuronidation activity (3, 4). Accumulation of the active metabolite SN-38 would increase toxicity of irinotecan.

The most common (wild-type) UGT1A1 allele is believed to be UGT1A1*1. The UGT1A1*28 allele is associated with a 2-base pair (bp) insertion (TA) in the TATA box in the promoter, resulting in the sequence (TA)₇TAA (the most common sequence is (TA)₆TAA). This nucleotide change in the promoter region is associated with the reduced expression of the protein and, therefore, with the decreased activity of SN-38 glucuronidation (a 50% decrease in UGT1A1*28/UGT1A1*28 patients and a 25% decrease

in UGT1A1*1/UGT1A1*28 patients compared with UGT1A1*1/UGT1A1*1 patients; ref. 4).

Taking into account both toxicity and compliance, a clinical dose-finding study established the recommended dose of irinotecan combined with the biweekly LV5FU2 regimen to be 180 mg/m² every 2 weeks, although MTD criteria were not met at doses up to 260 mg/m² (5).

Results from a genotype-driven phase I study suggested, however, that this recommended dose is considerably lower than the dose that can be tolerated by patients with normal SN-38 glucuronidation (6). Therefore, because there is a dose linearity of irinotecan pharmacokinetics with proportional increases in the AUC of both irinotecan and SN-38 with higher doses of irinotecan (7), dose intensification may be a way to optimize the efficacy of treatments in selected patients (6). The combination of high-dose irinotecan (260 mg/m²) with the simplified LV5FU2 regimen (HD-FOLFIRI regimen) was shown to be feasible with an acceptable safety profile and promising efficacy data (8).

The combination of 5-fluorouracil, irinotecan, and bevacizumab is a standard treatment for metastatic colorectal cancer (MCRC; ref. 9). Adding bevacizumab to this optimized chemotherapy regimen may be of interest.

The aim of this phase II study was to evaluate the tolerance and efficacy of the HD-FOLFIRI regimen in combination with bevacizumab (B) in patients with the UGT1A1 *1/*1 and *1/*28 genotypes.

Patients and Methods

Participants

This study was an open-label, nonrandomized, phase II trial. Patients 18 to 74 years old with a World Health Organization (WHO) performance status (PS) of less than 2 and nonresectable MCRC who had not previously been treated were eligible for inclusion if they exhibited the UGT1A1*1/*1 or UGT1A1*1/*28 genotype. We excluded patients with UGT1A1*28/*28 genotypes because this genotype is present in only 9.8% to 11% of the population (10) and would increase dramatically the number of patients to screen and to include and the time length of the study. Previous adjuvant chemotherapy without irinotecan was allowed if the last administration was performed at least 6 months before inclusion in the study. At least one lesion had to be measurable according to RECIST criteria. Patients had to have adequate bone marrow and liver and renal function (i.e., hemoglobin concentration ≥ 9 g/dL, neutrophil cell count $\geq 1.5 \times 10^9$ cells/L, platelet count $\geq 100 \times 10^9$ /L, serum bilirubin concentration ≤ 1.5 times the upper limit of normal, and alkaline phosphatase concentration ≤ 2.5 times the upper limit of normal; ≤ 5 times the upper limit of normal in cases of liver metastases). Patients were not eligible if they exhibited brain metastases or a serious concomitant medical disorder that would prevent the safe administration of chemotherapy or would be likely to interfere with study assessments. Written informed consent was obtained from all patients before study entry. The study was approved by the Boulogne-Billancourt Hospital (France) ethics committee and was registered at ClinicalTrials.gov, number NCT00628810.

Genotyping

UGT1A1 genotyping was performed on blood samples (10-mL EDTA tubes) after obtaining written consent from the patient. DNA was extracted using the QiAmp blood DNA extraction kit

(Qiagen) in the Laboratory of Biochemistry at the "Hospital Européen Georges Pompidou" in Paris. After quantification, DNA was stored at -20°C until genotyping was performed. The UGT1A1*28 allele of the gene was detected by fragment analysis. All alleles were characterized after the amplification of the DNA fragment using PCR by capillary electrophoresis for polymorphisms (9700 sequencing, Applied Biosystems). Genotyping results were sent within 10 days to the investigator.

Statistical considerations and trial design

The goal of adding targeted therapy to chemotherapy is generally to increase efficacy without increasing unacceptable toxicity. We have considered, after literature analysis, that a reasonable expected objective response rate (ORR) rate must be at least 60% (ORR for FOLFIRI Bevacizumab combination is around 58% (11), 49% for FOLFIRI (12), 54% for HD FOLFIRI (8), and the unacceptable level of severe toxicity must be under 20%.

Two groups of patients were considered according to their UGT1A1 genotype (Group 1: UGT1A1*1/UGT1A1*1; Group 2: UGT1A1*1/UGT1A1*28). The frequency of UGT1A1*28 alleles is reported to be about 32% in the Caucasian population (10). A Bryant and Day design was used with the ORR at 6 months and toxicity as the primary endpoints [independent review, H0: insufficient efficacy, ORR $\leq 40\%$; H1: expected efficacy ORR $\geq 60\%$, grade 4 or febrile neutropenia or grade 3–4 diarrhea (NCI CTC Version 2.0); H0: unacceptable toxicity, grade 3–4 toxicity $\geq 20\%$; H1: acceptable toxicity, grade 3–4 toxicity $\leq 5\%$]. An interim analysis was planned after the inclusion of 17 patients per group after 6 months of follow-up: if 7 patients or less had no objective response or/and 3 or more patients had unacceptable toxicity, the study would be stopped for futility, if 8 or more patients had an objective response or/and 2 or less patients had unacceptable grade 3–4 toxicity, 37 more patients per group were required for a total of 108 patients, 54 in each group, (α 5% and power 80%).

The secondary endpoints included progression-free survival (PFS) and overall survival (OS). PFS was calculated as the interval from the date of inclusion in the study to the first report of disease progression or death from any cause or cutoff date. OS was calculated as the interval from the date of inclusion until death from any cause or until the date of the last follow-up or cutoff date. The Kaplan–Meier method was used to estimate the OS and PFS curves.

The cutoff date for the final analysis was January 01, 2011. All analyses were based on the intent to treat principle. All tests were two sided, and *P* values less than 0.05 were regarded as significant. Data were analyzed using the STATA statistical software (version 10.0). In the absence of very serious adverse events, the study was planned not to stop enrollment during the interim analysis and finally 86 patients were included, we present here the results of the interim analysis and in parallel of the overall population included.

Treatment

Patients were treated with bevacizumab 5 mg/kg D1, irinotecan 260 mg/m² D1, LV 400 mg/m² D1, 5FU 400 mg/m² IV bolus D1, and 5FU 2,400 mg/m² 46-hour infusion D1-2 every 2 weeks. Treatment was started within 2 weeks after inclusion in the study.

Prophylactic G-CSF administration was not allowed as a primary prevention. G-CSF use was recommended in the case of grade 4 neutropenia for more than 7 days, febrile neutropenia, infection with concomitant grade 3–4 neutropenia, or nonrecovery of neutrophil cell counts $\geq 1,500/\text{mm}^3$ after 1 week.

Manfredi et al.




Figure 1. Study flow chart. †, 1 patient in group 2 was never treated because brain metastases were discovered after the patient's inclusion.

Drug dose reductions and delays in the case of hematologic or nonhematologic toxicities were detailed in the protocol. The treatment was stopped in the event of patient withdrawal, disease progression, or unacceptable toxic effects (nonhematologic grade 4 toxicity, nonrecovery from grade 3 toxicity after two dose adjustments, or nonrecovery after a 2-week treatment delay). Any dose reduction was permanent.

The tumor response was assessed every four cycles with CT or MRI according to the RECIST criteria. An objective response had to be confirmed by CT or MRI after 4 weeks. An external radiologic review was performed. Toxic effects were graded according to the National Cancer Institute Common Toxicity Criteria (version 2.0) until 4 weeks after the end of study treatments. At every visit, patients underwent history taking, physical examination, hematologic tests, and biochemical tests. An independent data monitoring committee reviewed the safety data on a regular basis.

Results

Patients were recruited between January 29, 2007, and January 30, 2008, for the first 34 patients analyzed in the interim analysis, December 11, 2008, for the final 86 included patients, at 20 centers in France. Thirty-four patients were analyzed in the interim analysis (IA; 17 in each group). As study inclusion was not stopped before the availability of the IA results, a total of 86 patients were included (40 patients in group 1 and 46 patients in group 2). One patient in group 2 was never treated because brain metastases were discovered after the patient's inclusion in the study. The flow chart of the study is presented in Fig. 1.

Patient characteristics

Interim analysis. The baseline characteristics of the patients analyzed in the interim analysis are presented in Table 1. The median patient age was 59 years (range: 52–75 years) in group 1 and 57

years (range: 44–72 years) in group 2. The WHO PS was 0–1 for 94.1% of the patients in both groups, but only 29.4% of the patients had a PS equal to 0 in group 1, compared with 52.9% in group 2. The primary tumor location was the colon and rectum in, respectively, 58.8% and 41.2% of the patients in group 1 and 88.2% and 11.8% of the patients in group 2. Patients of group 2 had more frequently liver metastasis than patients of group 1, respectively, 88.2% and 52.9%, lung metastasis was more frequent in group 1 than in group 2: 58.8% and 11.8%.

Overall population. The median population age was 59 and 61 years for group 1 and group 2. The WHO PS was 0–1, respectively, for 92.5% and 91.3% of the patients. The primary tumor location was the colon for 70.0% in the group 1 and 73.9% in the group 2. Liver metastasis rates were, respectively, 72.5% and 84.8% for group 1 and 2, 35.0% and 26.1% for lung metastasis.

Treatment administration

Interim analysis. The median duration of treatment was 14 months (range: 1–28 months) in group 1 and 6.5 months (range: 0–25 months) in group 2 (Table 2). The median dose per cycle for cycles 1 to 4 was similar in both groups, but the patients in group 2 received a median of 12 treatment cycles (range: 0–30 cycles), compared with 22 cycles (range: 4–38 cycles) for the patients in group 1.

Overall population. The median duration of treatment was similar in the two groups: 7.0 months. The median dose per cycles 1 to 4 was similar in the both groups, and the patients received the same median number of cycles: 14.5 for group 1 and 13.5 for group 2.

Primary endpoint results

Interim analysis. In both groups, the confirmed ORR, as estimated by the independent central review, was higher than the number (>7) required by the stopping rule [9 (52.9%) and 10 (58.8%) objective responses in group 1 and group 2, respectively].

Table 1. Patient characteristics at baseline

	Interim population <i>n</i> = 34		Overall population <i>N</i> = 86	
	Group 1 <i>n</i> = 17	Group 2 <i>n</i> = 17 ^a	Group 1 <i>n</i> = 40	Group 2 <i>n</i> = 46 ^a
Age, y				
Median (range)	59 (52–75)	57 (44–72)	59 (39–75)	61 (40–74)
WHO performance status	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
0	5 (29.4)	9 (52.9)	18 (45.0)	24 (52.2)
1	11 (64.7)	7 (41.2)	19 (47.5)	18 (39.1)
2	1 (5.9)	1 (5.9)	3 (7.5)	4 (8.7)
Sex	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
Male	11 (64.7)	11 (64.7)	24 (60.0)	29 (63.0)
Primary tumor location	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
Colon	10 (58.8)	15 (88.2)	28 (70.0)	34 (73.9)
Rectum	7 (41.2)	2 (11.8)	12 (30.0)	12 (26.1)
Metastatic sites	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
Liver	9 (52.9)	15 (88.2)	29 (72.5)	39 (84.8)
Lung	10 (58.8)	2 (11.8)	14 (35.0)	12 (26.1)
Peritoneum	0	2 (11.8)	5 (12.5)	9 (19.6)

NOTE: Group 1: UGT1A1*1/UGTA1*1; Group 2: UGT1A1*1/UGT1A1*28.

^a1 patient in group 2 was never treated because brain metastases were discovered after the patient's inclusion.

Three or more toxic events occurred in both groups (group 1: 7 events; group 2: 3 events), and the interim analysis stopping rules required less than 3 events to continue the trial (Table 3). The trial was therefore closed to inclusion after the results of the interim analysis.

Overall population. However, during the interim analysis and the availability of the results, recruitment was ongoing and finally a total of 86 patients were included (40 patients in group 1 and 46 patients in group 2). ORR was 45.0% in group 1 and 56.5% in group 2 and toxic events occurred for 11 patients and 8 patients, respectively.

Tolerance

Interim analysis. Toxicities by group are presented in Table 4. There was no death due to toxicity. All the patients experienced at least one adverse event, and 94.1% and 81.2% of the patients in group 1 and group 2, respectively, exhibited at least 1 grade 3–4 toxicity.

Severe diarrhea occurred in 23.5% of the patients in group 1 and in 12.5% of the patients in group 2, whereas severe neutropenia was more frequent in group 2 (37.5% vs. 29.4%).

Bevacizumab-related adverse events did not differ between the groups [except for grade 3–4 venous thromboembolic events (VTE), which occurred in 23.6% of patients in group 1 vs. 6.2% in group 2]. Arterial hypertension was observed in 23.5% of the patients in group 1 compared with 6.2% in group 2. Only one patient in each group exhibited grade 3 arterial hypertension. Approximately half of the patients exhibited epistaxis (mainly grade 1–2) in each group. Cerebral ischemia occurred in one patient in group 1.

Overall population. About 75.0% and 82.2% of patients of groups 1 and 2 exhibited at least one grade 3–4 toxicity. Severe diarrhea and VTE were more frequent in group 1 than in group 2, whereas severe neutropenia was more frequent in group 2 than in group 1. Arterial hypertension rate was similar in the both group. Epistaxis was equally frequent in the two groups.

PFS and OS on the overall population (Table 5)

The median PFS was 10.7 months (95% confidence intervals; CI, 8.5–13.1) in group 1 and 10.4 months (95% CI, 8.8–12.3) in group 2 (nonsignificant: NS). The median OS was 25.5 months

Table 2. Treatment administration

	Interim population <i>n</i> = 34		Overall population <i>N</i> = 86	
	Group 1 <i>n</i> = 17	Group 2 <i>n</i> = 17 ^a	Group 1 <i>n</i> = 40	Group 2 <i>n</i> = 46 ^a
Number of cycles	22 (4–38)	12 (0–30)	14.5 (3–38)	13.5 (0–40)
Median (range)				
Duration of treatment (mo)	14 (1–28)	6.5 (0–25)	7 (1–28)	7.0 (0–25)
Median (range)				
Dose per cycle (cycles 1 to 4), median (range)				
Bolus 5FU (mg/m ²)	392.9 (0; 410.2)	398.9 (0–419)	396.1 (0–411.0)	394.9 (0–419)
IV 5FU (mg/m ²)	2,357.4 (1633.4; 2474.0)	2,398.8 (0–2493.1)	2,389.4 (1633.4–2474.0)	2,393.1 (0–2493.1)
Irinotecan (mg/m ²)	255.2 (175.6; 264.3)	260.0 (0–270.6)	257.8 (162.8–264.3)	256.2 (0–270.6)
Bevacizumab (mg/kg)	5.0 (3.8; 5.0)	4.9 (0–5.3)	5.0 (3.8–5.2)	5.0 (0–5.4)

NOTE: Group 1: UGT1A1*1/UGTA1*1; Group 2: UGT1A1*1/UGT1A1*28.

^a1 patient in group 2 was never treated because brain metastases were discovered after the patient's inclusion.

Manfredi et al.

Table 3. Results of primary endpoint

	Interim population <i>n</i> = 34		Overall population <i>N</i> = 86	
	Group 1 <i>n</i> = 17	Group 2 <i>n</i> = 17 ^a	Group 1 <i>n</i> = 40	Group 2 <i>n</i> = 46 ^a
	Confirmed ORR <i>n</i> (%; interim analysis stopping rules required >7 events)	9 (52.9)	10 (58.8)	18 (45.0)
Considered toxic events total number of patients (interim analysis stopping rules required <3 events)	7	3	11	8
Grade 4 neutropenia	2 ^b	0	3 ^b	2 ^d
Febrile neutropenia	2	2 ^c	2	4 ^{c,d}
Grade 3 diarrhea	4 ^b	2 ^c	6 ^b	4 ^c
Grade 4 diarrhea	0	0	1	0

NOTE: Group 1: UGT1A1*1/UGT1A1*1; Group 2: UGT1A1*1/UGT1A1*28.

^a1 patient in group 2 was never treated because brain metastases were discovered after the patient's inclusion.^b1 patient with grade 4 neutropenia and grade 3 diarrhea.^c1 patient with febrile neutropenia and grade 3 diarrhea.^d1 patient with grade 4 neutropenia and febrile neutropenia.

(95% CI, 21.7–36.6) in group 1 and 23.9 months (95% CI, 18–37.1) in group 2 (NS).

Discussion

Optimization of medical treatment to improve efficacy with better tolerance is an important goal in the management of MCRC patients.

According to irinotecan metabolism, the standard dose of 180 mg/m² every 2 weeks may not be the optimal dose for patients with the UGT1A1*1/*1 or *1/*28 genotype (13). Previous studies demonstrated the feasibility and interest of higher doses of irinotecan in patients as monotherapy (7, 14) or in combination with 5FU: FOLFIRI regimen (8). The important interpatient variability for irinotecan pharmacokinetic can be, at least partly, explained by the UGT1A1*28 polymorphism (15).

The link between the UGT1A1*28 allele and the increase in SN-38 and the occurrence of diarrhea and leukopenia during irinotecan therapy suggested by retrospective studies (16–18) was

prospectively reported by Innocenti and colleagues (19). In this study, the UGT1A1 genotype and haplotype were correlated with SN-38 pharmacology and the incidence of severe neutropenia. The rate of grade 4 neutropenia was 50% among *28/*28 patients and 12.5% among *1/*28 patients, and there was no grade 4 neutropenia among *1/*1 patients. The prevalence of grade 3 diarrhea was 5% (1 *28/*28 and 2 *1/*28 patients, no grade 4 diarrhea). In the PETACC-3 trial, the risk of severe hematologic toxicity was increased among patients with homozygous UGT1A1*28 genotype (20). A recent meta-analysis reported that although the toxicity relationships were much stronger with the UGT1A1*28 homozygous variant, associations were also found with the UGT1A1*28 heterozygous variant (21). At least three prospective randomized phase III trials (22–24), however, did not confirm these initial results, suggesting that the influence of the UGT1A1*28 allele on the toxicity of irinotecan is modest and that its assessment should not be mandatory in routine clinical practice (23).

In a phase II study, 35 unselected patients were treated with the HD-FOLFIRI regimen as the first-line treatment of MCRC

Table 4. Adverse events (all cycles)

	Interim population <i>n</i> = 34				Overall population <i>N</i> = 86			
	Group 1 <i>n</i> = 17 <i>n</i> (%)		Group 2 <i>n</i> = 17 ^a <i>n</i> (%)		Group 1 <i>n</i> = 40 <i>n</i> (%)		Group 2 <i>n</i> = 46 ^a <i>n</i> (%)	
	All	Grade 3–4	All	Grade 3–4	All	Grade 3–4	All	Grade 3–4
Any	17 (100)	16 (94.1)	16 (100)	13 (81.2)	40 (100)	30 (75.0)	45 (100)	37 (82.2)
Unknown	0	0	1 ^a	1 ^a	0	0	1 ^a	1 ^a
Nonhematologic								
Diarrhea	12 (70.6)	4 (23.5)	11 (68.7)	2 (12.5)	30 (75.0)	7 (17.5)	30 (68.2)	4 (9.1)
Nausea	13 (76.5)	1 (5.9)	12 (75.0)	2 (12.5)	28 (70.0)	2 (5.0)	34 (77.3)	3 (6.8)
Vomiting	10 (58.8)	2 (11.8)	10 (62.5)	0 (0.0)	23 (57.5)	4 (10.0)	27 (61.3)	2 (4.5)
Epistaxis	9 (52.9)	1 (5.9)	7 (43.8)	0 (0.0)	19 (47.5)	1 (2.5)	19 (43.2)	0 (0.0)
Mucositis	8 (47.1)	0 (0.0)	9 (56.3)	0 (0.0)	17 (42.5)	2 (5.0)	20 (45.4)	2 (4.5)
Hypertension	4 (23.5)	1 (5.9)	1 (6.2)	1 (6.2)	8 (20.0)	3 (7.5)	8 (18.2)	4 (9.1)
Alopecia	6 (35.3)	0 (0.0)	6 (37.5)	2 (12.5)	14 (35.0)	0 (0.0)	18 (40.9)	6 (13.6)
VTE	7 (41.2)	4 (23.6)	2 (12.4)	1 (6.2)	8 (20.0)	5 (11.5)	2 (4.6)	2 (4.5)
ATE	1 (5.9)	1 (5.9)	0 (0.0)	0 (0.0)	2 (5.0)	2 (5.0)	0 (0.0)	0 (0.0)
Hematologic								
Neutropenia	13 (76.5)	5 (29.4)	14 (87.5)	6 (37.5)	28 (70.0)	10 (25.0)	34 (75.6)	14 (31.1)
Febrile neutropenia	2 (11.8)	2 (11.8)	2 (12.5)	2 (12.5)	4 (10.0)	2 (5.0)	5 (11.1)	4 (8.9)
Anemia	16 (94.1)	2 (11.8)	11 (68.7)	0 (0.0)	33 (82.5)	2 (5.0)	32 (70.5)	1 (2.2)
Thrombocytopenia	3 (17.7)	0 (0.0)	5 (31.2)	0 (0.0)	4 (10.0)	0 (0.0)	13 (28.9)	0 (0.0)

NOTE: Group 1: UGT1A1*1/UGT1A1*1; Group 2: UGT1A1*1/UGT1A1*28.

Abbreviations: VTE, venous thromboembolic event; ATE, arterial thromboembolic event.

^a1 patient in group 2 was never treated because brain metastases were discovered after the patient's inclusion.

Table 5. PFS and OS (overall population)

	Group 1 n = 40	Group 2 n = 46	P
Median PFS (mo)	10.7	10.4	0.8
IC (95%)	(8.5–13.1)	(8.8–12.3)	
Median OS (mo)	25.5	23.9	0.6
IC (95%)	(21.7–36.6)	(18.0–37.1)	

(8). The treatment administration was eventually delayed in 74% of the cases, and the dose was reduced in 43% of the cases. A granulocyte colony-stimulating factor G-CSF secondary prophylaxis to maintain cycle intervals and dose intensities was used in 37% of patients. There was one toxic death, and the main severe toxicities included neutropenia (74% of the patients), febrile neutropenia (11%), diarrhea (14%), and fatigue (17%; ref. 8). A recent meta-analysis (25) reported that UGT1A1*28 allele (homozygous, heterozygous, or wild-type) does not impact the survival in patient receiving irinotecan. In the present study, using the same chemotherapy regimen in combination with bevacizumab in selected patients with "favorable" UGT1A1 genotypes, the occurrence of severe neutropenia was much lower (29.7% in the *1/*1 and 37.5% in the *1/*28 genotype patient groups, respectively), whereas the occurrence of severe diarrhea was very similar in *1/*28 patients and, interestingly, 2-fold higher in *1/*1 patients.

A Bryant and Day design was used with a composite primary endpoint combining the ORR and toxicity. Toxicities associated with this primary endpoint included grade 4 neutropenia, febrile neutropenia, and grade 3–4 diarrhea.

Expected ORRs were reached in the two groups, but the trial was stopped at the interim analysis in both groups because the number of unacceptable toxicity was higher than the number defined in the stopping rules in the statistical analysis plan ($\geq 20\%$). Despite these initial events, toxicity was manageable. No toxic death and only one grade 4 diarrhea occurred (in group 1), and after a dose reduction, most of the patients continued to receive treatment with an acceptable tolerance for a median duration of treatment of 14 and 6.5 months in groups 1 and 2, respectively. A posteriori, and from a clinical point of view, it can be judged that the stopping rules of the trial based on the defined toxic events (that led to an early stop) were too stringent and not adapted to daily clinic.

There was, however, no clear benefit of the HD-FOLFIRI/bevacizumab combination with respect to efficacy. The observed ORRs (approximately 53%–59%) do not seem to be superior to those observed with the FOLFIRI regimen alone [49% in the trial by Douillard and colleagues (12) and 47.2% in the BICC-C trial (11)] or in combination with bevacizumab (58% in the BICC-C

trial). The addition of bevacizumab to the FOLFIRI HD regimen, compared with the trial by Ducreux and colleagues, in which a 54% ORR was reported, is also questionable (8).

In conclusion, this trial does not provide a convincing argument to support the adoption of the intensive treatment with HD-FOLFIRI plus bevacizumab combination for MCRC in patients with the UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*28 genotype. The overall response rate reached in our study is not superior to standard treatments.

Disclosure of Potential Conflicts of Interest

O. Bouché has received speakers bureau honoraria from Lilly. No potential conflicts of interest were disclosed by the other authors.

Disclaimer

The sponsor of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author and study statistician had full access to all of the data in the study and were ultimately responsible for the decision to submit the study for publication.

Authors' Contributions

Conception and design: O. Bouché, P. Rougier, J.-L. Legoux, T. Lecomte, E. Mitry, L. Bedenne

Development of methodology: P. Rougier, M.A. Lorient, T. Lecomte, L. Bedenne
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): O. Bouché, P. Rougier, M.A. Lorient, T. Aparicio, J.P. Lafargue, P.L. Etienne, C. Lécaille, J.-L. Legoux, T. Lecomte, F. Khemissa, G. Breysacher, P. Michel, E. Mitry, L. Bedenne

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Manfredi, K. Le Malicot, E. Maillard, T. Lecomte, E. Mitry

Writing, review, and/or revision of the manuscript: S. Manfredi, O. Bouché, P. Rougier, L. Dahan, T. Aparicio, K. Le Malicot, E. Maillard, T. Lecomte, E. Mitry, L. Bedenne

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Manfredi, C. Lécaille, K. Le Malicot, L. Bedenne
Study supervision: E. Mitry

Acknowledgments

The authors thank Marie Moreau, Floriane Ricard, and Franck Bonnetain.

Grant Support

All the authors received grants from La Ligue Nationale Contre le Cancer, Chugai, and Pfizer.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 21, 2015; revised August 5, 2015; accepted August 21, 2015; published OnlineFirst October 22, 2015.

References

- Ritter JK, Chen F, Sheen YY, Tran HM, Kimura S, Yeatman MT, et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. *J Biol Chem* 1992;267:3257–61.
- Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. *N Engl J Med* 1995;333:1171–5.
- Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. *Ann Oncol* 1998;9:845–7.
- Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, et al. Phenotype-genotype correlation of *in vitro* SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. *Clin Pharmacol Ther* 1999;65:576–82.
- Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. *J Clin Oncol* 1999;17:2901–8.
- Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. *J Clin Oncol* 2010;28:866–71.

Manfredi et al.

7. Ychou M, Raoul JL, Desseigne F, Borel C, Caroli-Bosc FX, Jacob JH, et al. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. *Cancer Chemother Pharmacol* 2002;50:383-91.
8. Ducreux M, Raoul JL, Marti P, Merrouche Y, Tigaud JM, Rebischung C, et al. High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases? *Oncology* 2008;74:17-24.
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004;350:2335-42.
10. Lampe JW, Bigler J, Horner NK, Potter JD. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. *Pharmacogenetics* 1999;9:341-9.
11. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. *J Clin Oncol* 2008;26:689-90.
12. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet* 2000;355:1041-7.
13. O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. *J Clin Oncol* 2006;24:4534-8.
14. Van Cutsem E, Dirix L, Van Laethem JL, Van Belle S, Borner M, Gonzalez Baron M, et al. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. *Br J Cancer* 2005;92:1055-62.
15. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. *J Clin Oncol* 1997;15:1502-10.
16. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. *Cancer Res* 2000;60:6921-6.
17. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. *Pharmacogenomics J* 2002;2:43-7.
18. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. *Clin Cancer Res* 2004;10:5151-9.
19. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. *J Clin Oncol* 2004;22:1382-8.
20. Roth A, Yan P, Dietrich D, Fiocca R, Bodoky G, Labianca R, et al. Is UGT1A1*28 homozygosity the strongest predictor for severe hematotoxicity in patients treated with 5-fluorouracil (5-FU)-irinotecan (IRI)? Results of the PETACC 3 - EORTC 40993 - SAKK 60/00 trial comparing IRI/5-FU/folinic acid (FA) to 5-FU/FA in stage II-III colon cancer (COC) patients. *J Clin Oncol* 26; 2008:187s (suppl; abstr 4036).
21. Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. *Pharmacogenomics J* 2014;14:120-9.
22. Boige V, Mendiboure J, Pignon JP, Lorient MA, Castaing M, Barrois M, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. *J Clin Oncol* 2010;28:2556-64.
23. Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. *J Clin Oncol* 2009;27:5519-28.
24. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. *J Clin Oncol* 2010;28:3227-33.
25. Dias MM, Pignon JP, Karapetis CS, Boige V, Glimelius B, Kweekel DM, et al. The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. *Pharmacogenomics J* 2014;14:424-31.

Molecular Cancer Therapeutics

High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study

Sylvain Manfredi, Olivier Bouché, Philippe Rougier, et al.

Mol Cancer Ther 2015;14:2782-2788. Published OnlineFirst October 22, 2015.

Updated version Access the most recent version of this article at:
doi:[10.1158/1535-7163.MCT-15-0293](https://doi.org/10.1158/1535-7163.MCT-15-0293)

Cited articles This article cites 25 articles, 13 of which you can access for free at:
<http://mct.aacrjournals.org/content/14/12/2782.full.html#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.